Relapsing multiple sclerosis (MS) and progressive MS are usually distinguished in MS, but it remains uncertain whether they reflect different neuropathological mechanisms. It is well established that disability accumulation is correlated with axonal injury, that the extent of axonal injury is correlated with the degree of inflammation and that a close association between inflammation and neurodegeneration exists in relapsing MS and progressive MS. 1 However, the inter-dependence between focal inflammation, diffuse inflammation and neurodegeneration and their relative contribution to clinical deficits, remains ambiguous.
Relapse is the key clinical expression of a focal lesion, but represents only a small part of the accumulation of focal events in the CNS as detected by MRI. It is clear that the clinical expression of a focal lesion is more dependant of the location of the focal lesions within the CNS than of the severity and the size of the tissue injury itself. However, the occurrence of relapses has been interpreted as a clinical marker of focal lesions in order to understand whether relapses, i.e. accumulation of focal lesions, might be or not a major determinant of disability progression. Whether or not relapses, including mild relapses, should be regarded as a delusion has be examined through a few epidemiological studies and clinical trials.
The Lyon cohort group 2-4 investigated the dates of disease onset and assignment of scores of irreversible disability (Disability Status Scale: DSS4, DSS6 and DSS7) in 1844 patients with MS. The main messages were the following. (a) The median times at which these irreversible DSS scores occurred were similar whether the disease was initially relapsing-remitting or progressive. (b) Early assessable clinical variables significantly influenced the time from the onset of MS to the assignment of a disability score of 4, but not the subsequent progression of irreversible disability. Median times from onset of MS to assignment of a score of 4, 6 and 7 were significantly influenced by the degree of recovery from the first relapse, time to a second neurological episode and the number of relapses in the first 5 years of the disease. In contrast, none of the variables substantially affected the time from a score of 4 to a score of 6 or 7, or from a score of 6 to a score of 7. (c) Among patients with the primary progressive or secondary progressive MS, the median time from the assignment of a score of 4 to a score of 6 or 7 or from a score of 6 to a score of 7 was not influenced by the presence or the absence of superimposed relapses.
The London Ontario group 5-8 investigated relationships between relapses and disability progression to DSS6, DSS8 and DSS10. The main messages were: (a) relapsing onset and progressive onset patients attained DSS3, DSS6, DSS8 and DSS10 at remarkably similar ages; (b) frequent relapses in the first 2 years and shorter first inter-attack intervals predicted shorter times to reach hard disability endpoints by increased probability and shorter latency to of entering the secondary progressive phase; (c) neither total number of relapsing-remitting phase attacks nor of relapses experienced during the relapsing-remitting phase after the second year up to onset of progression showed a deleterious effect on times from disease onset, from progression onset and from DSS3 to these hard endpoints. These results indicate a more complex relationship between relapses and disability accumulation than had been envisaged. The dissociation between relapses and progression implies that relapses (except possibly during years 1 and 2) are not a valid outcome surrogate for the late disability. These data should further discourage any direct causal relationship between clinical attack numbers and disability accumulation. Treatment of relapsing-remitting patients should be aimed at preventing or delaying features of the initial course, which associate with poor late outcome. Fred Lublin 9 investigated well-defined clinical trial databases selecting from placebo groups 224 relapsingremitting MS patients and found that 42% of the patients experiencing a relapse had a residual deficit ≥0.5 Expanded Disability Status Scale (EDSS) point and 28% had a lasting increase ≥1.0 EDSS point. Relapses produced measurable residual deficits; on average, the worsening attributable to a MS relapse amounts to 0.24 to 0.57 point on the EDSS scale. Relapse-associated step-wise worsening in patients with relapsing-remitting MS gives credence to the continued development of long-term treatment targeted at the early phases of the disorder.
In the Rennes cohort 10 the presence of residual deficit (EDSS ≥2) after the first relapse was strongly correlated with subsequent disability progression. Patients with early residual deficit reached DSS3 more rapidly than others. The number of relapses during the first 2 years in relapsing MS onset patients was strongly correlated with a shorter duration from MS clinical onset to DSS3 but did not modify the duration from DSS3 to DSS6. During the phase DSS3-DSS6, disability progression was more influenced by a previous conversion to secondary progressive than by occurrence of relapses. In summary the Rennes cohort clearly demonstrated that disability progression in the first phase of MS (to DSS3) does not influence disability progression during the second phase (DSS3 to DSS6). The duration of the second phase remained remarkably constant, as previously shown in the British Columbia MS population. 11 The correlation between early relapses and early disability progression has been shown in several studies. 2, 5, 7, 9, 10, 12 In contrast, late relapses after DSS3, 10 after year 2, 7 or after year 5 4,12 did not have a similar influence on disability progression in the majority of MS patients. The dissociation between later relapses and later disability progression has been repor ted. 2, 3, 6, 10, 12 The influence of early focal inflammatory clinical markers on disability progression restricted to phase 1 or to year 1-2 had been identified; 3, 5, 10 the Rennes cohort analysis demonstrated that their influence was restricted to phase 1 duration and to the relapsing onset phenotype. This was consistent with other observational studies 3 yielding the conclusion that once a clinical threshold of irreversible disability is reached, the progression of disability is amnesic of the prior clinical history of the disease.
The understanding about the dissociation between early and later disability progression and the role of relapses is central to the debate on the putative mechanisms of disability progression in MS. Some studies 4, 6, 8 have suggested that age is a key player (if not the only one) in the natural history of MS, leading to the concept of MS as a single-stage disorder with a chronic age-related neurodegeneration since the onset of the disease. 4 However, the Rennes cohort 10 suggests a two-stage disorder, with a first stage during which focal inflammatory lesions (having relapse as a clinical marker) influence disability progression, and a second stage during which disability progression is independent of focal inflammatory markers. In contrast, in the progressive onset phenotype, focal inflammatory lesions are clinically asymptomatic for a long period of time and only detectable on MRI, restricting the clear identification of the expected first stage of the disease.
The concept of MS as a two-stage disease is also supported by some MRI data, especially the plateauing relationship between T2 burden of disease and disability for EDSS value above 4.5, 13 and the strong correlation between T2 lesion load change within the first 5 years of MS and disability status at 20 years of disease duration. 14 It is also supported by therapeutic experience. With early therapeutic intervention, it is now easier to demonstrate a relationship between effects on the focal inflammatory lesions (relapses or new MRI lesions) and delaying confirmed disability progression in the short term, although at later stage of relapsing-remitting MS or secondary progressive MS the impact of these same therapies on disability progression remain uncertain. 15 Finally, this concept of MS as a two-stage disease has obvious implications for the future therapeutic strategy in MS, reinforcing the concept of therapeutic window of opportunity suggested by Coles. 15 Concerning whether or not mild relapse should be regarded as a delusion, my view is that at the early stage of the disease, in relapsing MS patients without progression, any clinical relapse, mild, moderate or severe, is a clinical biomarker of putative accumulation of new focal lesions and may be regarded as a potential higher risk of late disability progression. On the other hand, at later stage a mild relapse might be regarded as having no influence on the risk of disability progression. Thus, classifying relapses as mild, and thus of no consequence, is a delusion.
